A new study has suggested a link between semaglutide (the active ingredient in Wegovy and Ozempic) and a disproportionately increased reporting of suicidality.

Semaglutide has recently been treated as something of a wonder drug, with studies demonstrating it can reduce the risk of cardiovascular disease, stroke, and some cancers, and even suggesting it could treat addiction and neurodegenerative diseases.

However, the link with suicidal thoughts is not a new one. The FDA has an ongoing investigation into reports of suicidal thoughts or actions as a result of taking glucagon-like peptide-1 receptor agonists (GLP-1 Ras) like semaglutide and liraglutide.

The European Medicines Agency (EMA) Pharmacovigilance Risk Assessment Committee (PRAC) reviewed the data on the risk of suicidal thoughts and thoughts of self-harm related to GLP-1 Ras in 2023, and determined that there was no causal relationship.

In April 2024, PRAC concluded: “After reviewing the available evidence from non-clinical studies, clinical trials, post-marketing surveillance data and the available studies the PRAC considers that no update to the product information is warranted.”

The new study, conducted by an international team from the US, Switzerland and Italy, and published in JAMA, identified a “disproportionality signal of suicidal ideation with semaglutide”.

The authors say this remained significant when compared with dapagliflozin and metformin and in the subgroup of patients with co-reported use of antidepressants and benzodiazepines.

Conflicting data on suicidal thoughts risk with semaglutide

To reach these conclusions, the authors conducted an analysis of the World Health Organization (WHO) global database of suspected adverse drug reactions (ADRs) from September to December 2023.

Sensitivity analyses were conducted including patients with co-reported use of antidepressants and benzodiazepines and using dapagliflozin, metformin, and orlistat as comparators.

They conclude that “a detected signal of semaglutide-associated suicidal ideation warrants urgent clarification.”

The findings are at odds with the results of a January 2024 study by Case Western Reserve University School of Medicine researchers, which actually found a reduced risk for suicidal ideations with semaglutide.

The scientists examined around two million patients with type 2 diabetes or obesity and found no evidence to support the link between the drug and suicidal ideations.

Read the full paper here.

Diana Spencer, Senior Digital Content Editor, DDW